Oncology Practice Reviews & Product and Research & Development Theater Opportunities ~Philadelphia
|Event Date/Time: Jul 09, 2010||End Date/Time: Jul 10, 2010|
|Registration Date: Jun 25, 2010|
Oncology Practice Reviews is a 2-day symposium designed to educate community physicians on the state-of-the-art clinical management of a wide variety of solid tumors and hematologic malignancies. Lectures will highlight cutting-edge information and emerging treatment strategies for specific tumor types, including breast cancer, genitourinary malignancies, lymphoma, gastrointestinal malignancies, lung cancer, multiple myeloma, and chronic lymphocytic leukemia, in addition to other special topics unique to each meeting location. To enhance learning, participants will be engaged in solving â€œreal-worldâ€ problems through practical, interactive, case-based presentations.
Industry-led lectures and exhibits will be conducted in conjunction with this event to provide promotional product-specific information on available agents and products in development, respectively.
These optional activities are not certified for CME credit and are not planned or sanctioned by PER.
This educational program is directed toward medical oncologists and hematologists practicing in the community or academic setting who are interested in recent advances in the treatment of solid tumors and hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other physicians who care for patients with cancer, such as surgical oncologists, radiation oncologists, gynecologic oncologists, urologists, pulmonologists, gastroenterologists, family physicians, general practitioners, internists, cardiothoracic surgeons, general surgeons, gynecologists, radiologists, and pathologists, are also invited to attend.
At the conclusion of this symposium, you should be able to:
Assess the efficacy and safety of targeted agents in the management of patients with solid tumors and hematologic malignancies
Identify results of recent clinical trials that are currently applicable to the management of patients with solid tumors and hematologic malignancies